Clinical Trials · NCT02135445
Safety and Efficacy of TAK-385 for Patients With Localized Prostate Cancer
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- Millennium Pharmaceuticals, Inc.
- Enrollment
- 103
- Start date
- Jun 2014
- Locations
- 25 sites, United States, United Kingdom
- Primary endpoint
- Percentage of Participants With Effective Castration Rate Over 25 Weeks